GHIT Fund Request For Proposals: Hit-to-Lead Platform (HTLP)
The Global Health Innovative Technology Fund (GHIT Fund) is a non-profit organization focused on promoting the discovery and development of new health technologies, including drugs, vaccines, and diagnostics for infectious diseases prevalent in developing countries.
The GHIT Fund is pleased to announce investment opportunities for one of its platforms: Hit-to-Lead Platform (HTLP).
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behaviour, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Proposals must meet the criteria below in order to be eligible for consideration:
- Cellular potency consistent with potential to deliver lead series (typically Plasmodium spp. IC50 <1µM, T. cruzi intracellular IC50 <10 µM, L. donovani intracellular IC50 <10µM, and Mycobacterium tuberculosis MIC <10µM).
- Compounds originated/derived from Japan
- Novel hit structures confirmed
- Primary results validated on hit compounds (>90% pure)
- Acceptable in vitro concentration-response curves
- Preliminary SAR with existing analogues
- Progressable chemotypes
- >10-fold selectivity for cytotoxicity using a mammalian cell line (e.g. HepG2)
- Adequate selectivity in counter assay(s)
- No blocking intellectual property (IP)
- No major synthesis or formulation issues anticipated
The GHIT Fund requires each HTLP project to have a collaboration with one of the three leading drug development PDPs as a partner: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).
Read more here.
Proposals deadline February 28, 2020 (10:00 am Tokyo time).